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In this issue of Chemistry & Biology, Cognetta et al. (2015) describe new pharmacological tools, including
N-hydroxyhydantoin-containing carbamate inhibitors and an activity-based probe, for palmitoyl protein thio-
esterase 1 and alpha, beta-hydrolase domain-4 that expand the toolkit for the serine hydrolases.Serine hydrolases are involved in a
number of physiological andpathophysio-
logical processes, including neurotrans-
mission, digestion, immune response,
and the clotting cascade (Bachovchin
and Cravatt, 2012). The enzymes catalyze
the hydrolysis of esters, amides, or thio-
esters using a base-activated serine
nucleophile. There are roughly 240 pre-
dicted serine hydrolases in the mamma-
lian proteome,with one-half characterized
as metabolic serine hydrolases and the
other half as serine proteases/peptidases
(Bachovchin and Cravatt, 2012). Meta-
bolic serinehydrolaseshydrolyze endoge-
nous small molecules and some of the
substrates and their cognate enzymes
are well characterized; for example, the
neurotransmitter acetylcholine is cleaved
(and inactivated) by acetylcholinesterase
(ACHE); the endocannabinoids 2-arachi-
donoylglycerol and anandamide are hy-
drolyzed by monoacylglycerol lipase and
fatty acid amide hydrolase, respectively;
and neutral lipids, such as triacylglycerols
and cholesteryl esters, are hydrolyzed by
adipose triglyceride lipase and hormone-
sensitive lipase. However, the physiolog-
ical functions of most mammalian serine
hydrolases remain poorly characterized.
The majority of serine hydrolases in
mammals still lack selective inhibitors
for their functional characterization in
terms of their endogenous substrates
and cellular functions. Absence of effec-
tive small-molecule probes or pharmaco-
logical tools for the bulk of this enzyme
class limits the systematic analysis of pro-
tein function. To address this gap, activ-
ity-based protein profiling (ABPP) enables
the activities of enzymes with conserved
catalytic mechanisms, such as the serine
hydrolases, to be evaluated in their native808 Chemistry & Biology 22, July 23, 2015 ª2environments within tissues and cells (Ni-
phakis and Cravatt, 2014). This chemo-
proteomic strategy has been extremely
useful for identifying selective and potent
small molecule inhibitors of several mem-
bers of the serine hydrolase superfamily,
including those that are uncharacterized
in terms of their substrates and products.
The most potent serine hydrolase inhibi-
tors are those that covalently modify and
irreversibly inactivate the catalytic serine
nucleophile. Of the various small mole-
cules that chemically react with the serine
residue, the carbamates have proven to
be a versatile chemotype for inhibiting
the activity of serine hydrolases. The
carbamate chemotype has been used
for a long time as an electrophile that
can complement the nucleophilic serine
residue in serine hydrolases, resulting in
the formation of a covalent bond between
the electrophilic carbonyl carbon and the
serine oxygen nucleophile (Figure 1A).
For example, N-methylcarbamates have
been used as pesticides since the 1950s
and exert their toxicity by acting as
a slowly turned-over ACHE substrate,
effectively leading to the irreversible
inactivation of ACHE and the buildup of
the neurotransmitter acetylcholine in the
synaptic cleft (Casida and Durkin, 2013).
More recently, the carbamate chemotype
has been embedded into various chemi-
cal scaffolds and developed as chemical
probes and pharmaceuticals to treat
disease (Bachovchin and Cravatt, 2012).
Depending on the structure of the stay-
ing group, the covalent carbamylated-
enzyme adduct that is produced is essen-
tially irreversible and enzyme function is
inactivated (Crow et al., 2012).
In this issue, Cognetta et al. (2015)
describe a library of N-hydroxyhydantoin015 Elsevier Ltd All rights reserved(NHH)-containing carbamate inhibitors
that evolved from related N-hydroxysuc-
cinimide (NHS)-containing carbamates
(Chang et al., 2013). As noted by the au-
thors, the substrate selectivity of enzymes
is predictive of features important for
inhibitor binding, and the catalytic effi-
ciencies of serine hydrolases are strongly
influenced by the leaving group structures
of substrates. Therefore, the objective of
their study was to increase the number
of carbamate inhibitors by diversifying
the structures of its leaving group. The
rationale was that these new compounds
would have the potential to engage
previously untargeted serine hydrolases
in proteomes and provide leads for further
structural optimization. TheNHH-contain-
ing carbamate was chosen as a scaffold
over N-hydroxysuccinimide because of
the greater potential for structural diversi-
fication of the NHH-containing leaving
group (Figure 1B). Further modifications
were made to both the staying (carba-
mylating) and leaving (NHH) groups to
optimize potency and selectivity. Struc-
tural refinement of the lead compounds
provided a group of compounds that
selectively inhibited a number of serine hy-
drolases whose activities had previously
not been inhibited by small molecules.
These included alpha, beta-hydrolase
domain-4 (ABHD4) and palmitoyl protein
thioesterase 1 (PPT1). ABHD4 hydrolyzes
N-acyl phospholipids (Lee et al., 2015),
whereas PPT1 removes fatty acyl groups
from cysteine residues in proteins (Lu
and Hofmann, 2006). The biological func-
tion of these hydrolases in vivo, however,
remains enigmatic. A potent and selective
inhibitor of PPT1, designated ABC44, was
identified with an IC50 of 0.1 mM (in situ,
ABPP). Remarkably, of the 44 serine
Figure 1. Development of N-Hydroxyhydantoin-Containing Carbamate Inhibitors and a
Tailored Activity-Based ABC45 that Enable the Study of Previously Difficult to Analyze Serine
Hydrolases Such as PPT1
(A) The base-activated serine nucleophile of the serine hydrolase is covalently modified by the electrophilic
carbamate chemotype (leaving group is shown in red; the carbamylating group is shown in black).
(B) Cognetta et al. (2015) describe new inhibitors in which the N-hydroxyhydantoin-containing leaving
group (shown in red) was synthetically modified to afford new inhibitors that selectively inactivate palmitoyl
protein thioesterase 1 (PPT1) and ABHD4. This scaffold was used to generate an alkyne-tagged activity-
based chemoproteomic probe (termed ABC45) that reacts directly with PPT1 and ABHD4 in complex
proteomes.
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man PC3 cell line by ABPP-SILAC (stable
isotope-labeling by amino acids in cell
culture) following in situ treatment with
ABC44 (0.1 mM, 4 hr), the only detectable
off-targetswereABHD6andCPVL.Devel-
opment of selective NHH carbamate in-
hibitors with restricted reactivity not only
provided leads for drug development
but also a novel activity-based probe to
characterize previously difficult to analyze
serine hydrolases. The synthesis of a
tailored activity-based probe (ABC45;
Figure 1B), which is an alkyne-containing
clickable probe, provides a tool that can
directly read out the activity state of
PPT1 and ABHD4 in native biological sys-
tems. This is an important contribution to
the chemoproteomic toolkit, because the
broad-based serine hydrolase activity
probe fluorophosphonate-rhodamine (or
biotin) does not react efficiently with these
particular enzymes. Our own work had
previously shown this for PPT1 (Wanget al., 2013). The synthesis of the tailored
activity-based probe ABC45 with the
clickable alkyne tag will be useful for
studying PPT1 in intact cells and animal
models. It will also permit the develop-
ment of more potent and selective inhibi-
tors that will enable its function to be per-
turbed in different physiological contexts.
Mutations in PPT1 that inactivate enzyme
activity cause a rare neurological disease
termed infantile neuronal ceroid lipofusci-
nosis (INCL), but the biochemical basis for
thepathology is unclear. In addition tonew
chemical tools applied to PPT1, a first-
generation inhibitor of ABHD4 was also
developed that showed good selectivity.
ABHD4 in cells and tissues was also
directly labeled by the new activity-based
probe ABC45, which will help to guide
future studies that optimize the potency
and selectivity of the ABHD4 inhibitors.
Thus, the study by Cognetta et al.
(2015) provides new pharmacological
tools that target serine hydrolases PPT1Chemistry & Biology 22, July 23, 2015and ABHD4 with good selectivity in vivo.
These enzymes had heretofore been
difficult to study because of their lack of
reactivity toward broad-based fluoro-
phosphonate activity-based probes. The
new inhibitors and tailored activity-based
probes will be useful as chemical probes
to investigate the function of these en-
zymes in cell and animal models and will
also serve as leads for drug development.
The findings of the paper add to the
remarkable list of chemical tools that
have been developed for the serine hy-
drolase class. These have been vitally
important contributions to the research
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